NT-219
- Generic Name
- NT-219
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14BrNO5S
- CAS Number
- 1198078-60-2
- Unique Ingredient Identifier
- K1WT1A1UP5
NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Phase 1
Not yet recruiting
- Conditions
- Head and Neck CancerHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 29
- Registration Number
- NCT06919666
- Locations
- 🇺🇸
Universtiy of Colorado Hospital, Aurora, Colorado, United States
🇺🇸UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado, United States
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
Phase 1
Active, not recruiting
- Conditions
- Squamous Cell Carcinoma of Head and NeckColorectal AdenocarcinomaHead and Neck CancerSolid Tumor, AdultMetastatic Solid TumorRecurrent Solid Tumor
- Interventions
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- TyrNovo Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT04474470
- Locations
- 🇺🇸
California Cancer Associates for Research and Excellence, Encinitas, California, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸UCSD Moores Cancer Center, San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath